Compare GIL & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GIL | ERAS |
|---|---|---|
| Founded | 1946 | 2018 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Building Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.1B | 6.3B |
| IPO Year | 1999 | 2021 |
| Metric | GIL | ERAS |
|---|---|---|
| Price | $32.99 | $13.60 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 10 |
| Target Price | ★ $50.88 | $25.10 |
| AVG Volume (30 Days) | 1.9M | ★ 5.1M |
| Earning Date | 11-05-2026 | 11-12-2026 |
| Dividend Yield | ★ 2.93% | N/A |
| EPS Growth | N/A | ★ 36.23 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $53.26 | N/A |
| Revenue Next Year | $0.39 | N/A |
| P/E Ratio | $23.11 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $31.34 | $2.81 |
| 52 Week High | $73.70 | $24.28 |
| Indicator | GIL | ERAS |
|---|---|---|
| Relative Strength Index (RSI) | 33.25 | 42.80 |
| Support Level | $31.34 | $13.18 |
| Resistance Level | $43.16 | $15.71 |
| Average True Range (ATR) | 1.61 | 1.31 |
| MACD | -0.16 | -0.13 |
| Stochastic Oscillator | 17.51 | 14.12 |
Gildan is a vertically integrated designer and manufacturer of basic apparel, including T-shirts, underwear, socks, and hosiery. It is a leader in blank T-shirts, sweatshirts, and other apparel to wholesalers, major clothing brands, and printers (printwear). Gildan also sells branded clothing through retail and direct-to-consumer channels, a business that was greatly enhanced by the Hanesbrands acquisition in 2025. Gildan's labels include Hanes, Bali, Maidenform, Playtex, Gildan, American Apparel, Comfort Colors, and Goldtoe. Gildan produces most of its clothing at factories in Latin America but has been ramping up production at its new facility in Bangladesh. Incorporated in 1984, the Montreal-based company operates internationally but generated 90% of its sales in the US in 2025.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.